Tuesday, December 09, 2008 1:58:40 AM
[Too bad Barry Bonds' health (mental) is questionable...)
http://www.mercurynews.com/ci_11162279?IADID
By MALCOLM RITTER AP Science Writer
Posted: 12/07/2008 10:29:07 AM PST
NEW YORK—Healthy people should have the right to boost their brains with pills, like those prescribed for hyperactive kids or memory-impaired older folks, several scientists contend in a provocative commentary.
College students are already illegally taking prescription stimulants like Ritalin to help them study, and demand for such drugs is likely to grow elsewhere, they say.
"We should welcome new methods of improving our brain function," and doing it with pills is no more morally objectionable than eating right or getting a good night's sleep, these experts wrote in an opinion piece published online Sunday by the journal Nature.
The commentary calls for more research and a variety of steps for managing the risks.
As more effective brain-boosting pills are developed, demand for them is likely to grow among middle-aged people who want youthful memory powers and multitasking workers who need to keep track of multiple demands, said one commentary author, brain scientist Martha Farah of the University of Pennsylvania.
"Almost everybody is going to want to use it," Farah said.
"I would be the first in line if safe and effective drugs were developed that trumped caffeine," another author, Michael Gazzaniga of the University of California, Santa Barbara, declared in an e-mail.
The seven authors, from the United States and Britain, include ethics experts and the editor-in-chief of Nature as well as scientists. They developed their case at a seminar funded by Nature and Rockefeller University in New York. Two authors said they consult for pharmaceutical companies; Farah said she had no such financial ties. Some health experts agreed that the issue deserves attention. But the commentary didn't impress Leigh Turner of the University of Minnesota Center for Bioethics.
"It's a nice puff piece for selling medications for people who don't have an illness of any kind," Turner said.
The commentary cites a 2001 survey of about 11,000 American college students that found 4 percent had used prescription stimulants illegally in the prior year. But at some colleges, the figure was as high as 25 percent.
"It's a felony, but it's being done," Farah said.
The stimulants Adderall and Ritalin are prescribed mainly for people with attention deficit hyperactivity disorder, but they can help other people focus their attention and handle information in their heads, the commentary says.
Another drug called Provigil is approved for sleep disorders but is also prescribed for healthy people who need to stay alert when sleep-deprived, the commentary says. Lab studies show it can also perk up the brains of well-rested people. And some drugs developed for Alzheimer's disease also provide a modest memory boost, it says.
Ritalin is made by Switzerland-based Novartis AG, but the drug is also available generically. Adderall is made by U.K.-based Shire PLC and Montvale, N.J.-based Barr Pharmaceuticals Inc., and some formulations are also available generically. Provigil is made by Cephalon Inc. of Frazer, Pa.
While supporting the concept that healthy adults should be able to use brain-boosting drugs, the authors called for:
— More research into the use, benefits and risks of such drugs. Much is unknown about the current medications, such as the risk of dependency when used for this purpose, the commentary said. Also, according to the Food and Drug Administration, Adderall, for example, is an amphetamine that carries warnings about possible sudden death, heart attack and stroke, especially for people with heart problems.
— Policies to guard against people being coerced into taking them.
— Steps to keep the benefits from making socio-economic inequalities worse.
— Action by doctors, educators and others to develop policies on the use of such drugs by healthy people.
— Legislative action to allow drug companies to market the drugs to healthy people if they meet regulatory standards for safety and effectiveness.
Dr. Nora Volkow, director of the National Institute on Drug Abuse, said she agreed with the commentary that the nonprescribed use of brain-boosting drugs must be studied.
But she said she was concerned that wider use of stimulants could lead more people to become addicted to them. That's what happened decades ago when they were widely prescribed for a variety of disorders, she said.
"Whether we like it or not, that property of stimulants is not going to go away," she said.
Erik Parens, a senior research scholar at the Hastings Center, a bioethics think tank in Garrison, N.Y., said the commentary makes a convincing case that "we ought to be opening this up for public scrutiny and public conversation."
One challenge will be finding ways to protect people against subtle coercion to use the drugs, the kind of thing parents feel when neighbor kids sign up for SAT prep courses, he said.
And if the nation moves to providing a basic package of health care to all its citizens, it's hard to see how it could afford to include brain-boosting drugs, he said. If they have to be bought separately, it raises the question about promoting societal inequalities, he said.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM